Perfusion Medical
Perfusion Medical is dedicated to commercializing PEG-20k, a revolutionary drug designed to treat hemorrhagic shock and other ischemic conditions. With over $18 million in funding from the Department of Defense and numerous studies supporting its efficacy, the company aims to improve patient outcomes significantly.
Industries
N/A
Nr. of Employees
small (1-50)
Products
Investigational high-molecular-weight polyethylene glycol intravenous resuscitation solution (investigational)
An investigational intravenous solution formulated with high-molecular-weight polyethylene glycol intended to reduce ischemic tissue swelling, decompress capillaries, restore microcirculatory perfusion, and improve oxygen delivery in hemorrhagic shock and other ischemic conditions.
PM-208
PM-208 is an intravenous solution that aims to correct ischemic injury and severe hypovolemic shock through the non-energetic unidirectional transfer of isotonic water out of ischemically swollen tissues and into capillaries.
PEG-20k
An intravenous solution utilizing Polyethylene Glycol (PEG) at a specific molecular size to draw water out of swollen cells, relieve capillary pressure, and restore blood flow following severe blood loss.
Investigational high-molecular-weight polyethylene glycol intravenous resuscitation solution (investigational)
An investigational intravenous solution formulated with high-molecular-weight polyethylene glycol intended to reduce ischemic tissue swelling, decompress capillaries, restore microcirculatory perfusion, and improve oxygen delivery in hemorrhagic shock and other ischemic conditions.
PM-208
PM-208 is an intravenous solution that aims to correct ischemic injury and severe hypovolemic shock through the non-energetic unidirectional transfer of isotonic water out of ischemically swollen tissues and into capillaries.
PEG-20k
An intravenous solution utilizing Polyethylene Glycol (PEG) at a specific molecular size to draw water out of swollen cells, relieve capillary pressure, and restore blood flow following severe blood loss.
Services
Coordination and management of contract research organizations and external vendors for preclinical testing, regulatory support, and legal/IP services.
Program-level management of preclinical-to-commercial development activities, funding coordination, and commercialization planning.
Coordination and management of contract research organizations and external vendors for preclinical testing, regulatory support, and legal/IP services.
Program-level management of preclinical-to-commercial development activities, funding coordination, and commercialization planning.
Expertise Areas
- Trauma resuscitation therapeutics
- Preclinical large-animal efficacy studies
- Intravenous formulation and CMC development
- Regulatory strategy for investigational IV therapeutics
Key Technologies
- High-molecular-weight polyethylene glycol IV formulations
- Large-animal hemorrhagic shock models (swine, rodent)
- Osmotic-gradient-based tissue decompression mechanism
- Physiological monitoring of perfusion and coronary perfusion pressure